What is the recommended initial management for a patient presenting with acute coronary syndrome?

Initial Management of Acute Coronary Syndrome

Immediately administer dual antiplatelet therapy with aspirin plus ticagrelor or prasugrel (preferred over clopidogrel) for all ACS patients undergoing percutaneous coronary intervention, along with parenteral anticoagulation, and proceed urgently to coronary angiography with revascularization based on ACS subtype 1, 2.

Immediate Actions (Within 10 Minutes)

• Obtain 12-lead ECG immediately to distinguish STEMI from non-ST-elevation ACS (NSTE-ACS) 3
• Administer aspirin to all patients unless contraindicated 4
• Start oxygen only if hypoxemic (not routinely for all patients)
• Provide nitroglycerin and morphine for chest pain relief 4

Antiplatelet and Anticoagulation Strategy

Dual antiplatelet therapy is mandatory for at least 12 months 1, 2:

• Aspirin plus ticagrelor or prasugrel (strongly preferred over clopidogrel) for patients undergoing PCI 1, 2
• For NSTE-ACS with delayed angiography (>24 hours), upstream clopidogrel or ticagrelor may be considered 1, 2
• Add parenteral anticoagulation: unfractionated heparin, low-molecular-weight heparin, bivalirudin, or fondaparinux 4

Critical bleeding prevention measures 1, 2:

• Proton pump inhibitor for patients at gastrointestinal bleeding risk
• Consider ticagrelor monotherapy ≥1 month post-PCI in patients who tolerate initial dual therapy
• For patients requiring long-term anticoagulation, discontinue aspirin 1-4 weeks post-PCI, continue P2Y12 inhibitor (preferably clopidogrel)

Revascularization Strategy: STEMI vs. NSTE-ACS

For STEMI (30% of ACS cases):

Primary PCI within 120 minutes is the gold standard and reduces mortality from 9% to 7% 3:

• Use radial approach over femoral to reduce bleeding, vascular complications, and death 1
• Intracoronary imaging recommended for complex lesions 1
• If PCI cannot be achieved within 120 minutes, administer fibrinolytic therapy (alteplase, reteplase, or tenecteplase at full dose for age <75 years; half dose for ≥75 years), then transfer for PCI within 24 hours 3

For NSTE-ACS (70% of ACS cases):

Invasive coronary angiography within 24-48 hours for high-risk patients reduces mortality from 6.5% to 4.9% 3:

• PCI is recommended; fibrinolytic therapy is NOT recommended 4
• Complete revascularization strategy is recommended for both STEMI and NSTE-ACS 1
• For multivessel disease in STEMI, perform multivessel PCI in single procedure (preferred) or staged 1

Critical exception: In ACS with cardiogenic shock, emergency revascularization of culprit vessel only; do NOT perform routine PCI of non-infarct arteries at initial procedure 1

Additional Medical Therapies

• Statin therapy (high-intensity) 4, 5
• Beta-blocker therapy 4, 5
• ACE inhibitor or ARB 4
• SGLT-2 inhibitor therapy 5

Special Considerations

Cardiogenic Shock:

Microaxial flow pump use is reasonable in selected patients to reduce death, but complications (bleeding, limb ischemia, renal failure) are higher; requires careful vascular access management and weaning 1, 2

Anemia:

Red blood cell transfusion to maintain hemoglobin of 10 g/dL may be reasonable in patients with ACS and acute/chronic anemia who are not actively bleeding 1, 2

Multivessel Disease:

Complete revascularization is recommended; choice between CABG vs. multivessel PCI depends on coronary disease complexity and comorbidities 1

Common Pitfalls to Avoid

• Do not delay ECG beyond 10 minutes of presentation 3
• Do not use clopidogrel when ticagrelor or prasugrel are available for PCI patients 1, 2
• Do not perform routine multivessel PCI during initial procedure in cardiogenic shock 1
• Do not use fibrinolytic therapy for NSTE-ACS 4
• Do not forget PPI prophylaxis in high GI bleeding risk patients 1, 2
• Do not use femoral approach when radial access is feasible 1